# Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

> **NCT05661188** · PHASE2 · RECRUITING · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 45 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Anal Canal

## Interventions

- **DRUG:** Atezolizumab plus Tiraglolumab

## Key facts

- **NCT ID:** NCT05661188
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-14
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05661188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05661188, "Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05661188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*